Edesa Biotech is trading 5.43% up at $4.85, rebounding after recent financing news, although causation is unconfirmed.
- Shares rebounded from the August 27 close of $4.60, when they fell 6.88%.
- No new company-specific announcement explaining the August 28 move was identified; the latest notable filing was the August 20 pricing of a $25 million public offering.
- Major indexes are up less than 0.5%, leaving the definitive catalyst unclear.